FRISCO, Texas, Dec. 17, 2007 (PRIME NEWSWIRE) -- John Pentony, Publisher of Stockguru.com announced today that the company has posted a new Podcast Interview featuring Renhuang Pharmaceuticals, Inc. (OTCBB:RHGP). John Pentony interviews Mr. Li Shaoming, CEO and Chairman of the Board, for Renhuang Pharmaceuticals. In the interview Mr. Li discusses the company and its recent news from the company including its recently announced Olympic year prime time television ad space on China Central Television (also known as "CCTV").
To listen to the interview, please visit:
http://www.stockguru.com/podcasts/?p=21
For a comprehensive profile of on the company, please visit:
http://www.stockguru.com/profiles/rhgp/
About Renhuang Pharmaceuticals, Inc.
Renhuang Pharmaceuticals, located in the city of Harbin in China's Heilongjiang Province, is a leading integrated developer, manufacturer and distributor of a broad array of high-quality nutraceutical, natural medicinal and bio-pharmaceutical products. The Company's three major product lines are Acanthopanax-based natural medicinal products, Shark Power Health Care series and Traditional Chinese Medicines. Renhuang's key product line is Acanthopanax-based products, a natural medicine for treating depression and melancholy and offering various other health benefits. Renhuang controls an estimated 70% of China's natural resource of Acanthopanax (also known as Siberian Ginseng), giving it a dominant position in the market for Acanthopanax-based natural medicines.
Renhuang distributes its products through a multi-level sales network with over 2000 sales agents. Its products are sold domestically and exported to Russia and Southeast Asia. The Company has established a multi-channel research and development infrastructure consisting of in-house researchers, a post-doctoral working center, and collaboration with well known institutions and scientists. In manufacturing, the Company strictly follows the international GMP certified quality standards and systems using cutting-edge technology, state of the art equipment, and proprietary innovative and award winning processes. To learn more about Renhuang Pharmaceuticals, visit www.renhuang.com.
About StockGuru.com
StockGuru.com features daily alerts going out three times daily to members. To join our email alert list, please visit:
http://www.stockguru.com/joinlist.php
To feature your publicly traded company in our alerts, or to discuss our complete services, please contact John Pentony at (469) 252-3031 or email publisher@stockguru.com.
Safe Harbor Statement
This press release contains certain statements that may include 'forward-looking statements' as defined in the Securities Act of 1933, and the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included herein are 'forward-looking statements.' Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release.
The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with and available from the Securities and Exchange Commission. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Disclosure: Pentony Enterprises LLC expects to be compensated as much at $12,300 for profile coverage from StockPromoters.com. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.